The Smart Investor
    Facebook Instagram
    Tuesday, August 16
    Facebook Instagram LinkedIn
    The Smart Investor
    • Home
    • About
      • About Us
      • Careers
    • Smart Investing
      • Getting Started
      • Investing Strategy
      • Smart Analysis
      • Smart Reads
    • Special Free Reports!
    • As Featured on BT
    • Our Services
      • Our Services
      • Subscribe now!
    • Login
    • Cart
    The Smart Investor
    Home»Blue Chips»3 Pandemic-Resistant Stocks for Your Watchlist
    Blue Chips

    3 Pandemic-Resistant Stocks for Your Watchlist

    Royston YangBy Royston YangApril 13, 2020Updated:July 8, 20204 Mins Read
    Facebook Twitter LinkedIn Email WhatsApp
    Share
    Facebook Twitter LinkedIn Email WhatsApp

    Businesses around the world are facing tremendous stress as countries curb travel, close their borders and shutter their factories.

    As such, it’s probably fair to say that few businesses remain unscathed.

    These companies may be in industries that are recession-resistant or have natural monopolies that make them more resilient during a downturn.

    Given the favourable characteristics, investors should actively seek out such companies as they stand a very strong chance of getting through the pandemic without significant adverse effects.

    With that in mind, here are three such pandemic-resistant stocks that investors can consider for their portfolios.

    Singapore Exchange Limited (SGX: S68)

    Singapore Exchange Limited, or SGX, is Singapore’s sole stock exchange operator.

    Last month, SGX announced that it will stay open during the COVID-19 circuit breaker period.

    Keeping the exchanges open will allow investors and fund managers to continue using its risk management tools and a vast array of derivatives and securities to manage their portfolios.

    And with heightened volatility in stock markets around the world, SGX’s suite of products continues to see a surge in demand.

    For its securities division, market turnover increased by 124% year on year in March to S$48.2 billion, while securities daily average value (SDAV) jumped 114% year on year.

    Total derivatives traded volume rose 41% year on year to 33 million contracts.

    With this pandemic unlikely to abate anytime soon, SGX’s securities and derivatives division could continue to see a healthy level of interest.

    As more trades are made on its platform, SGX could gain higher revenues, profits and cash flow for the group.

    Raffles Medical Group Ltd (SGX: BSL)

    Raffles Medical Group Ltd, or RMG, is an integrated healthcare provider. The group owns the flagship Raffles Hospital located in Bugis and a chain of clinics offering private family medicine and health screening services.

    Being in the healthcare industry, RMG directly contributes to the fight against COVID-19.

    Beyond Singapore, RMG is one of the few pre-qualified private hospital operators in China, underscoring the need for quality medical care in China.

    RMG’s new hospital in Chongqing, China has started operations since January 2019 and has been included in China’s social health insurance scheme Yibao.

    That said, the virus could delay the opening of RMG’s other hospital in Shanghai.

    RMG CEO Dr Loo has mentioned that the completion of the hospital could be postponed to sometime during the third quarter of this year.

    The group’s China hospitals will also incur start-up losses during their first three years of operation but for long term investors, it may be well worth the wait.

    Top Glove Holdings Berhad (SGX: BVA)

    Top Glove is the world’s largest manufacturer of gloves. The group has 2,000 customers worldwide and exports to more than 195 countries.

    As of 19 March 2020, Top Glove has 44 factories and a glove production capacity of 73.4 billion pieces per annum.

    The pandemic has greatly increased demand for nitrile gloves to be used in the healthcare industry.

    As a result, Top Glove’s order book has increased, with strong sales orders coming from Europe and the USA along with the Asian region.

    At the moment, Top Glove’s factory utilisation rate is now close to 100%, but the group is expanding its capacity by building three new factories and installing more production lines.

    When completed, the new facilities should add an additional capacity of 8.2 billion gloves per annum by end-2020.

    Further down the road, another 9.5 billion gloves per annum of new capacity is expected to be available by the end of 2021, bringing Top Glove’s production capacity to a record 91.1 billion.

    As demand is likely to remain high for the foreseeable future, Top Glove’s order book should continue to see healthy growth.

    With share prices battered to multi-year lows, many attractive investment opportunities have emerged. In a special FREE report, we show you 3 stocks that we think will be suitable for our portfolio. Simply click here to scoop up your FREE copy… before the next stock market rally.

    Disclaimer: Royston Yang owns shares in Singapore Exchange Limited and Raffles Medical Group Ltd.

    Yahoo
    Share. Facebook Twitter LinkedIn Email WhatsApp

    Related Posts

    ComfortDelGro Declares a Special Dividend: 7 Things You Should Know About the Land Transport Giant’s Latest Earnings

    August 16, 2022

    The Investing Checklist of Legendary Growth Investor Phillip Fisher: Part 5

    August 15, 2022

    ST Engineering’s Order Book Hits $22.2 Billion: 5 Highlights from the Group’s Latest Earnings

    August 15, 2022
    Facebook Instagram LinkedIn Telegram
    • Careers
    • Disclaimer & Privacy Policy
    • Subscription Terms of Service
    © 2022 The Smart Investor. All Rights Reserved. The Smart Investor, thesmartinvestor.com.sg, an investment education website managed by The Investing Hustle Pte Ltd (Company Reg No. 201933459Z) is not licensed or otherwise regulated by the Monetary Authority of Singapore, and in particular, is not licensed or regulated to carry on business in providing any financial advisory service. Accordingly, any information provided on this site is meant purely for informational and investor educational purposes and should not be relied upon as financial advice. No information is presented with the intention to induce any reader to buy, sell, or hold a particular investment product or class of investment products. Rather, the information is presented for the purpose and intentions of educating readers on matters relating to financial literacy and investor education. Accordingly, any statement of opinion on this site is wholly generic and not tailored to take into account the personal needs and unique circumstances of any reader. The Smart Investor does not recommend any particular course of action in relation to any investment product or class of investment products. Readers are encouraged to exercise their own judgment and have regard to their own personal needs and circumstances before making any investment decision, and not rely on any statement of opinion that may be found on this site.

    Type above and press Enter to search. Press Esc to cancel.